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Welcome to this new report designed to provide our partners, policy makers, and the public with detailed 
information on CDC’s programs at the National 
Center for HIV/AIDS, Viral Hepatitis, STD, and 
TB Prevention (NCHHSTP).  This report aims to 
provide an overview of our work, our priorities, 
and activities, and how these contribute to 
improving health for the communities we serve. 
We have prepared this report in the interest of 
fulfilling our Center’s commitment to improved 
transparency and accountability.
Fiscal Year 2007 was truly a new beginning 
for our Center. During this time, NCHHSTP was 
formally approved as a new organizational unit, 
with the addition of viral hepatitis prevention 
to our mission, as part of the reorganization 
of the CDC Coordinating Center for Infectious 
Diseases (CCID). We were particularly pleased 
to be rated as an effective program by the Office 
of Management and Budget PART process. 
Substantial gains were made in improving health 
and health impact in many arenas – whether 
implementing new guidelines on HIV testing 
in the United States; supporting HPV vaccine 
implementation in the United States; releasing 
new prevention guidelines for viral hepatitis; 
achieving further reductions in TB incidence; 
or supporting the successful implementation of 
the President’s Emergency Plan for AIDS Relief 
(PEPFAR). In all domains, NCHHSTP staff and 
our partners continue to make a difference in 
the lives of many around the world.
 
NCHHSTP continues to evolve, and we are 
committed to ensuring that we not only actively 
support CDC and HHS priorities, but that we 
continue to listen and learn from those infected 
with, or affected by, HIV/AIDS, viral hepatitis, 
STDs, and tuberculosis. During Fiscal Year 
2007 the Center refocused its commitment 
to reducing health disparities, increasing 
program collaboration and service integration, 
and maximizing global synergies by ensuring 
better collaboration across programs and more 
holistic and comprehensive prevention services 
for those in need. This report highlights some 
of this evolution and how our investments and 
resources are contributing to achieving CDC’s 
overarching health protection goals focused on 
creating healthy people, places, global health, 
and preparedness.
As always, a report such as this could not have 
been done without the work of many. We 
gratefully acknowledge the collaboration of 
our staff and partners, and other professionals 
working in the field of HIV, viral hepatitis, STD, 
and TB prevention. Thank you for your leadership, 
creativity, commitment, and continued support 
for our work and mission.
I hope that you enjoy reading this report about 
the center’s new beginning in 2007. If you 
would like more information about NCHHSTP 
programs, please visit our Web site at
http://www.cdc.gov/nchhstp/
 
Kevin A. Fenton  M.D., Ph.D, F.F.P.H. 
Director, National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention
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 History  
The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) is part of the Centers for Disease 
Control and Prevention (CDC), an agency of the 
U.S. Department of Health and Human Services 
(HHS). It is one of four national centers housed 
within CDC’s Coordinating Center for Infectious 
Diseases (CCID). 
The National Center for HIV, STD, and TB 
Prevention (NCHSTP) was established in 1994 
to bring together most of CDC’s HIV prevention 
activities under a single organizational home 
with its sexually transmitted disease (STD) 
prevention and tuberculosis (TB) elimination 
programs. In 2000, the Global AIDS Program 
(GAP) was added to NCHSTP in response to the 
global human immunodeficiency virus/acquired 
immunodeficiency syndrome (HIV/AIDS) 
epidemic. In 2006, CDC’s Division of Viral 
Hepatitis (DVH) was added, and the Center was 
renamed the National Center for HIV/AIDS, 
Viral Hepatitis, STD, and TB Prevention. 
The diseases addressed by NCHHSTP share a 
number of commonalities. They have similar 
or overlapping at-risk populations—including 
racial and ethnic minorities, men who have 
sex with men (MSM), and injection drug users 
(IDUs). These diseases also have important 
interactions. Those who are infected with 
certain STDs, such as syphilis or gonorrhea, 
are at greater risk for HIV infection. Likewise, 
those who are infected with HIV are far more 
susceptible to TB disease because their immune 
systems are weakened. 
These diseases also share similar social 
determinants, including poor access to health 
care, stigma, discrimination, homophobia, and 
poverty. In the area of prevention and control, 
effective, science-based interventions exist to 
reduce the burden of TB, viral hepatitis, most 
STDs, and HIV.
Mission 
NCHHSTP maximizes public health and safety 
nationally and internationally through the 
elimination, prevention, and control of disease, 
disability, and death caused by HIV/AIDS, non-
HIV retroviruses, viral hepatitis, other STDs, TB, 
and non-TB mycobacteria. 
 
NCHHSTP achieves its mission by: 
• Developing, implementing, and evaluating 
effective science-based prevention programs 
for HIV, viral hepatitis, STDs, and TB.  
• Developing high-quality research and 
translating relevant findings into a prevention 
policy and programs. 
• Creating and strengthening strategic 
relationships and networks with individuals 
and organizations. 
• Strengthening and promoting surveillance 
activities and findings for program planning, 
public health response, and evaluation.  
Who Are We? 
As a leader in preventing and controlling HIV 
infection, viral hepatitis, STDs, and TB, NCHHSTP 
applies well-integrated, multidisciplinary 
programs of research, surveillance, risk factor 
and disease intervention, and evaluation. 
NCHHSTP addresses domestic HIV/AIDS 
prevention through an array of public health 
activities, including monitoring the disease’s 
impact, facilitating and supporting partnerships, 
implementing prevention programs, 
conducting intervention research and program 
evaluation, delivering technical assistance to 
build the capacity of organizations to offer 
prevention services, and developing policy and 
communications to support HIV prevention. 
These activities are conducted with a wide 
range of public- and private-sector partners, 
including state and local health departments, 
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community-based organizations (CBOs), 
and other nongovernmental organizations, 
universities, businesses, and the media. 
NCHHSTP aims to prevent viral hepatitis 
infections and their acute and chronic liver 
disease consequences. CDC educates health 
care and public health professionals to improve 
identification of persons at risk for chronic 
hepatitis C infection, and ensures appropriate 
counseling, diagnosis, management, and 
treatment. NCHHSTP also conducts research 
and policy development to control hepatitis A 
and B, and supports surveillance to monitor 
who is getting infected with hepatitis B and 
to ensure appropriate counseling, testing, and 
medical management of infected persons. 
To prevent STDs, NCHHSTP provides national 
leadership through research, surveillance, 
policy development, and assistance to states, 
territories, and local health departments. 
NCHHSTP also provides Federal support for a 
community-wide, science-based, interdisciplinary 
systems approach to STD prevention and 
conducts prevention research to improve the 
methods and delivery of prevention services as 
well as to develop and refine interventions. The 
Center’s focus areas include preventing STD-
related infertility in women, preventing adverse 
outcomes of pregnancy, preventing cancer 
related to sexually transmitted infections (STI), 
and preventing STI-related HIV transmission.
NCHHSTP provides leadership and assistance to 
domestic and international efforts to prevent, 
control, and eliminate TB. NCHHSTP provides 
grants to states and other entities for prevention 
and control services, researches the prevention 
and control of TB, funds demonstration 
projects, and sponsors public information and 
education programs. In addition, the Center 
supports education, training, and clinical skills 
improvement activities to prevent, control, 
and eliminate TB. NCHHSTP also manages the 
national TB surveillance system and provides 
laboratory support for TB control activities. 
Since more than half of the U.S. TB cases are 
among those born outside of the United States, 
one of the TB program’s chief aims is to prevent 
and control TB among foreign-born persons. 
NCHHSTP also includes GAP, which was initiated 
in 2000 to address the international HIV/AIDS 
epidemic by assisting resource-constrained 
countries. GAP assists these countries in 
1) preventing HIV infection; 2) improving 
treatment, care, and support for people living 
with HIV; and 3) building vital capacity and 
infrastructure to address the global HIV/AIDS 
epidemic. GAP’s highly trained physicians, 
epidemiologists, public health advisors, 
behavioral scientists, and laboratory scientists 
support the national HIV/AIDS strategies of 
more than 60 countries in Africa, Asia, Central 
and South America, and the Caribbean through 
its country and regional offices. In 2003, when 
the President’s Emergency Plan for AIDS Relief 
(PEPFAR) was announced, GAP joined this 
unified USG response to global HIV/AIDS.
  
Where Are We? 
NCHHSTP employs a cadre of dedicated staff 
to accomplish its domestic and international 
objectives. Almost 1,400 staff work in 
NCHHSTP’s offices in Atlanta, Georgia. In 
addition, 285 staff are assigned to field offices 
in 29 states, the District of Columbia and Puerto 
Rico. NCHHSTP also employs approximately 
1,200 direct hires, contractors, fellows, and 
locally employed staff working in international 
field offices in more than 30 countries.  
 
NCHHSTP Key Priorities
NCHHSTP has three key priorities that are 
guiding center-wide initiatives and focusing 
work group activities in 2007: 
• Reducing health disparities 
• Encouraging program collaboration and 
service integration 
• Maximizing global synergies 
These priorities support NCHHSTP’s overall 
mission and programs. In 2007 NCHHSTP 
established eight internal workgroups to address 
these three key programmatic priorities. These 
workgroups are focusing on topics such as 
health issues in corrections facilities, surveillance 
and strategic information, and use of modeling 
and health results measures as tools to aid 
prevention efforts.  
 
Reducing Health Disparities 
NCHHSTP aims to improve the health of 
populations disproportionately affected by HIV, 
viral hepatitis, STDs, TB, and other related 
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 diseases and conditions and ultimately to help 
eliminate health disparities. The Center’s Office 
of Health Disparities (OHD) leads this effort. 
A health disparity is the difference that separates 
a group of interest from a reference group for 
an indicator of health that is measured in terms 
of a rate, proportion, mean, or some other 
quantitative measure. The ultimate aim of this 
priority is to improve the health of populations 
disproportionately affected by HIV/AIDS, viral 
hepatitis, STDs, TB, and other related diseases 
and conditions, and ultimately to help eliminate 
health disparities. Populations include racial 
and ethnic minorities, women, incarcerated 
persons, sexual minorities, and other persons 
disproportionately affected by these diseases 
and conditions.
 
OHD coordinates and tracks health disparity 
activities within the Center and provides 
leadership in support of research, surveillance, 
education, training, and program development 
to reduce health disparities. OHD also manages 
the Tuskegee Health Benefit Program and works 
with NCHHSTP leadership to promote a diverse 
public health workforce through internships, 
fellowships, training programs, and other 
activities.
Major accomplishments and activities in 2007 
aimed at reducing health disparities include:  
• Health Disparities Report—In 2007 
NCHHSTP released Health Disparities in HIV/
AIDS, Viral Hepatitis, Sexually Transmitted 
Diseases, and Tuberculosis in the United 
States: Issues, Burden and Response report. 
This retrospective review of CDC surveillance 
data for HIV/AIDS, viral hepatitis, STDs, and 
TB from 2000 to 2004 includes information 
on some of the CDC programmatic, 
educational, and research activities that 
have been implemented to address health 
disparities related to those diseases. This is 
the first integrated surveillance report of its 
kind for NCHHSTP. 
 
• Evaluation of the Tuskegee Health Benefit 
Program—The Tuskegee Health Benefit 
Program is a congressionally mandated 
program that provides comprehensive 
lifetime medical and health benefits to the 
affected widows and offspring of study 
participants of the Tuskegee syphilis study. 
The evaluation of the benefit program was 
conducted using existing administrative, 
financial, and programmatic data to describe 
how the program operates and determine 
cost and service utilization for FY 2000 to 
2006. Key evaluation findings include 1) 
a demographic shift from a relatively older 
population of study participants and their 
wives to a younger population of primarily 
female offspring; 2) medical care and 
nursing home costs that account for most of 
the expenditures; and 3) total expenditures 
declined over the period, with a trend toward 
increasing individual costs noted. The results 
will assist in strengthening the program and 
planning for the health needs of the current 
participants.  
• Consultations on Health Disparities 
Issues—NCHHSTP held two consultations 
on addressing health disparities in minority 
communities during FY 2007. In June the 
Center’s STD prevention division convened 
the Consultation to Address STD Disparities 
in African American Communities to bring 
together community leaders and other partners 
serving African American communities to help 
identify prevention and control efforts likely 
to be acceptable and effective in affected 
communities. Several key themes emerged, 
including the need to engage grassroots 
community members and the utility of 
framing STD disparities messages within 
 broader sexual health or health disparities 
 issues. Consultants identified a range of 
 possible strategies, including improving access 
to available services, focusing interventions 
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Other FY 2007 Accomplishments: 
Reducing Health Disparities 
• Establishment of cross-NCHHSTP 
   workgroup on health disparities, 
   corrections, and MSM 
• Launch of new Web pages on 
   lesbian, gay, bisexual, and 
   transgender  health
 
• Work commenced on an NCHHSTP 
 white paper on "Social Determinants 
of HIV/AIDS, Viral Hepatitis, STD, 
and TB Risk Among Ethnic/Racial 
and Sexual Minorities and Other 
Special Populations."
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on young men, and building coalitions. The 
 meeting report is posted on the CDC Web 
site ( http://www.cdc.gov/std/general/
STDHealthDisparitiesConsultationJune200
7.pdf ), and the well-received background 
papers prepared for the consultation are to 
be published in a special issue of the journal 
Sexually Transmitted Diseases. 
 
NCHHSTP also held a consultation on HIV/
AIDS and African American women in June 
2007. More than 50 participants, including 
government officials and staff from public 
health agencies and CBOs, attended to share 
their collective knowledge and skills and 
to generate suggestions for HIV prevention 
strategies for underserved African American 
women most affected by HIV/AIDS. Meeting 
participants identified a number of cross-
cutting issues in African American women’s 
lives that place women at risk for HIV. They 
questioned what can be done to give young 
African American women the skills they need 
to reduce risk and provided suggestions on how 
public health agencies and a range of CBOs 
and stakeholder organizations could assess 
and manage the HIV/AIDS crisis among African 
American women.
Encouraging Program 
Collaboration and Service 
Integration 
Program collaboration and service integration 
(PCSI) is a major strategic priority for NCHHSTP. 
The Office of Program Collaboration and Service 
Integration was established in FY 2007 to 
analyze and develop policies, and to promote 
and oversee activities that foster PCSI.
In the context of NCHHSTP activities, PCSI is 
defined as “a mechanism of organizing and 
blending interrelated health issues, separate 
activities, and services in order to maximize 
public health impact through new and 
established linkages to facilitate the delivery 
of services.” Integration of prevention services 
is focused at the field or client level. PCSI’s 
goal is to provide prevention services that are 
holistic, evidence-based, comprehensive, and 
high quality to appropriate populations at every 
interaction with the health care system.  
Site Visits to State and Local Programs—
During FY 2007 NCHHSTP’s director and 
staff continued the program of local site visits 
(initiated in 2006) by traveling to California and 
New York to learn more about what state and 
local health departments are doing to provide 
greater integration of HIV, viral hepatitis, STD, 
and TB services. The team visited a broad 
sampling of state, county, city, and community 
agencies and programs funded directly by CDC 
or indirectly through health departments, as 
well as with lesbian, gay, bisexual, transgender 
(LGBT) health centers, CBOs, STD clinics, and 
prisons. The site visits gave NCHHSTP staff 
an opportunity to examine how state and 
local public health agencies were providing 
integrated, client-centered programs in the field 
and to understand the challenges of PCSI efforts. 
External Consultation on PCSI—NCHHSTP 
convened an External Consultation on Program 
Collaboration and Service Integration in Atlanta, 
Georgia, on August 21-22, 2007. The purpose 
of the consultation was to engage key NCHHSTP 
program stakeholders in developing and 
refining the National Center’s vision and 
objectives for PCSI and to plan and prioritize 
PCSI activities over the next 5 years. The more 
than 120 participants included a broad range of 
internal and external stakeholders—NCHHSTP 
leadership and staff and representatives from 
40 state and local HIV, TB, STD, and hepatitis 
programs; other Federal agencies; national 
organizations; and CBOs funded by NCHHSTP.
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Other FY 2007 Accomplishments: 
Program Collaboration and Service Integration 
• Appointment of associate director 
for program integration 
• Development of NCHHSTP PCSI 
Green Paper 
• Internal organizational realignment 
for PCSI 
• Leaders-to-Leaders meetings with 
other Federal Agencies 
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 Action steps resulting from the consultation 
included: 
• Developing a policy framework to help 
facilitate dialogue on what works and what 
needs strengthening.  
• Exploring funding opportunities for program 
collaboration and service integration efforts. 
• Focusing our efforts in three priority areas: 
 1) integrated surveillance; 2) integrated 
funding guidance in program announcements; 
and 3) integrated staff training and skills 
development. 
 
Maximizing Global Synergies 
NCHHSTP has an increasingly global focus, as 
evidenced by the rapid expansion of GAP  and 
the mobilizing of activities focused on addressing 
drug resistance. In today’s world, success in 
prevention requires interdependent relationships 
that are global in nature. NCHHSTP’s imperative 
to maximize global synergies promotes 
interdependent programmatic relationships 
between NCHHSTP divisions that have a global 
focus. The goal is to ensure active collaboration 
between these divisions to take full advantage of 
opportunities for leveraging NCHHSTP, CCID, and 
CDC resources, and to maximize health impact. 
With this imperative, NCHHSTP actively pursues 
and seeks input about international program 
development and public health research, fosters 
robust internal and external partnerships, and 
commits to novel and participatory approaches  
    for implementation and dissemination.
Following are some activities that support this 
priority:
• NCHHSTP Global Perinatal Working Group—
The Center launched a Global Perinatal 
Workgroup in FY 2007, which draws on 
staff from across CDC to collaborate on this 
important issue. Perinatal diseases, such as 
perinatal AIDS and congenital syphilis, are a 
major concern, both globally and in the United 
States. The workgroup pulls together expertise 
from multiple CDC programs within three 
national centers—the National Center for 
Zoonotic, Vector-Borne, and Enteric Diseases 
(NCZVED), the National Center for Chronic 
Disease Prevention and Health Promotion 
(NCCDPHP), and NCHHSTP. In partnership 
with existing coalitions, partners, and other 
USG agencies, this CDC group, chaired by 
GAP, aims to leverage infrastructure, skills, 
and expertise to advocate for, implement, 
and evaluate integrated services delivered 
during the perinatal period. The workgroup 
has been meeting biweekly since January 
2007 to develop Healthy Mothers/Healthy 
Babies—Integrating Services in the Perinatal 
Period, an integrated package of services 
administered during the perinatal period in 
developing countries.   
• Mobilization Against MDR TB and XDR 
TB—The importance of maximizing global 
synergies was also evidenced in the global 
mobilization against the rise of multidrug-
resistant (MDR) and extensively drug-
resistant (XDR) TB. NCHHSTP’s Division of 
Tuberculosis Elimination (DTBE) and GAP 
have been providing technical assistance 
in their efforts to address drug-resistant TB 
globally. Another example of the global efforts 
against drug resistance is the NCHHSTP’s 
Division of STD Prevention (DSTDP) work 
providing support and technical assistance to 
international efforts to monitor antimicrobial-
resistant gonorrhea.
 
• The links between domestic and international 
prevention efforts can also be seen in programs 
such as GAP’s HIV Prevention in Care and 
Treatment Settings—an intervention for HIV-
infected individuals in sub-Saharan Africa. The 
intervention was adapted from Partnership 
for Health, an evidence-based intervention 
used in the United States that produced a 
decrease in reported sexual risk behaviors 
among HIV-positive patients who received 
brief prevention messages from their health 
care providers. CDC, along with key partners, 
piloted this clinic-based, provider-delivered 
intervention in Kenya and is now rolling it 
 out to countries throughout Africa. This 3- to 
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Other FY 2007 Accomplishments: 
Maximizing Global Synergies 
• Leadership retreat identified infant 
mortality as focus area 
•  Established monthly NCHHSTP global 
coordination meeting 
• Worked with partners to continue 
implementation of PEPFAR
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5-minute intervention gives providers the 
tools and skills to deliver targeted prevention 
messages to HIV-positive patients at the end 
of every routine clinic visit. Messages focus 
on disclosure of HIV status, partner testing, 
reduction of transmission to others, and 
prevention of other STIs. 
Partnerships 
NCHHSTP works in collaboration with 
governmental and nongovernmental partners 
at community, state, national, and international 
levels. NCHHSTP funds prevention efforts, 
demonstration projects, capacity-building 
efforts, and surveillance activities in state, local, 
and territorial health departments, as well as 
CBOs and national organizations.
NCHHSTP provides leadership and strengthens 
related efforts of other Federal agencies without 
duplicating efforts. NCHHSTP coordinates its 
efforts with several other agencies within HHS. 
For example, the Health Resources and Services 
Administration (HRSA) is authorized under the 
Ryan White HIV/AIDS Treatment Modernization 
Act to support treatment programs for people 
living with HIV and AIDS, and HRSA uses data 
from NCHHSTP’s surveillance systems to guide 
funding for these programs. NCHHSTP HIV/AIDS 
surveillance data are also used to guide funding 
for the U.S. Department of Housing and Urban 
Development’s (HUD’s) Housing Opportunities 
for People with AIDS program. 
NCHHSTP also reaches out to partners in 
business, media, and other groups. For 
example, NCHHSTP’s director, in partnership 
with the Kaiser Family Foundation, met with 
Black Entertainment Television’s (BET) news 
and public affairs staff on the issue of HIV/
AIDS in the African American community. This 
meeting was a forum to provide real stories of 
those living with and working to eradicate HIV/
AIDS in the Black community.
  
Raising Awareness 
NCHHSTP works to raise awareness about 
HIV/AIDS, viral hepatitis, STDs, and TB by 
providing information on prevention topics. 
In FY 2007, NCHHSTP made a number of 
enhancements to its Internet information 
offerings.
These include the following:
 
• Redesign of www.hivtest.org, along with 
activities promoting National HIV Testing Day 
resulted in a 31 percent increase in visits to 
the site for June 2007, compared to June 
2006. In addition, the number of visits to 
the site in June 2007 (125,413) increased 
by 80 percent over the average number of 
monthly visits between January and May 
2007. The Web site provides HIV testing 
locations to Web site visitors by zip code. 
• Implementation of Google Maps on both 
www.cdcnpin.org and www.hivtest.org to 
facilitate finding the location of HIV, STD, and 
TB organizations as well as testing sites.  
• Development of CDC’s first Internet pages 
on LGBT Health www.cdc.gov/lgbthealth/, 
which includes content from across the 
agency. This has been widely viewed and 
praised by stakeholders. Since its launch in 
July 2007, the site has had nearly 20,000 
visitors. 
•  Addition of more than a dozen new Web 
items from NCHHSTP on CDC.gov since 
the site’s redesign launch in April 2007, 
including: HIV Testing during Pregnancy, 
Reducing STDs and Health Costs, Stop TB 
among African Americans, Tuskegee Syphilis 
Study, and Raising Awareness about Human 
Papillomavirus (HPV).  
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 A Year In Review:  
Program Accomplishments 
To have the largest impact on the epidemics, NCHHSTP uses a comprehensive approach to prevention that incorporates 
surveillance, research, prevention interventions, 
and evaluation. NCHHSTP’s surveillance and 
research activities help to better define and 
understand the epidemics across the nation, 
and inform the targeting and development of 
prevention strategies. The Center’s prevention 
interventions and capacity-building efforts are 
based on behavioral, laboratory, and medical 
science, and work to contain the spread of 
HIV/AIDS, STDs, viral hepatitis, and TB. 
Program evaluation and policy research and 
development assess intervention effectiveness 
and refine prevention approaches. 
NCHHSTP’s comprehensive prevention 
programs have been evaluated externally and 
found to be effective. In an FY 2007 review 
of NCHHSTP’s domestic programs by the Office 
of Management and Budget (OMB), NCHHSTP 
received the top rating of “Effective.” Programs 
rated “Effective” set ambitious goals, achieve 
results, are well-managed, and improve 
efficiency. OMB rates all Federal programs with 
a standard questionnaire called the Program 
Assessment Rating Tool (PART). The PART 
program rating indicates how well a program is 
performing so the public can see how effectively 
tax dollars are being spent. 
In 2005 CDC established Health Protection 
Goals for the nation. NCHHSTP’s program 
areas are primarily included in three of CDC’s 
four overarching Health Protection Goals—the 
goals focusing on healthy people in every stage 
of life, healthy people in a healthy world, and 
healthy people in healthy places. Following are 
examples of NCHHSTP programmatic activities 
and accomplishments in FY 2007, by goal 
area.
  
Healthy People in 
Every Stage of Life 
CDC’s primary mission is to reduce health 
risks, at all stages of life, through the most 
efficient and effective means possible. CDC’s 
healthy people in every stage of life goal is 
articulated as “all people, especially those at 
greater risk of health disparities, will achieve 
their optimal lifespan with the best possible 
quality of health in every stage of life.” Some 
highlights follow of NCHHSTP’s FY 2007 key 
accomplishments and activities related to this 
goal area.  
 
The Heightened National Response to the 
HIV/AIDS Crisis Among African Americans 
HIV remains a persistent and pervasive threat 
to the health, well-being, and human potential 
of many African Americans. In 2005 blacks 
made up approximately 13 percent of the 
population, but accounted for nearly half (49 
percent) of the new HIV diagnoses in the 33 
states with long-term, confidential, name-based 
HIV surveillance.
To address this health disparity in FY 2007, 
NCHHSTP launched a “Heightened National 
Response to the HIV/AIDS Crisis among 
African Americans.” The response includes four 
key strategy areas: 1) expand the reach of 
prevention services; 2) increase opportunities 
for diagnosing and treating HIV; 3) develop 
new, effective prevention interventions; and 4) 
mobilize broader community action. 
On March 8, 2007, CDC convened a partnership 
meeting of influential leaders from the African 
American community, CBO and faith-based 
organizations, entertainment, and public 
health. During the meeting, African American 
leaders were called on to build a “black AIDS 
mobilization” to end the debilitating stigma of 
HIV/AIDS in the African American community. 
African American leaders responded by sharing 
personal and organizational commitments to 
increase awareness, communicate more about 
HIV/AIDS, and encourage African Americans to 
seek early diagnosis and treatment.
The leaders represented such diverse 
organizations as The Links, Jack and Jill, Inc., 
the National Coalition of 100 Black Women, 
the National Urban League, and 100 Black Men 
of America, Inc. There were also representatives 
from historically black colleges and universities, 
megachurches, and large corporations, such as 
Aetna and UPS.
Of the 80 leaders who attended, the vast 
majority (84%) made commitments to develop 
and conduct a program to fight HIV/AIDS in 
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their communities. In the first 6 months, there 
has been progress in every sector, from arts and 
entertainment to business; from civic groups to 
elected officials; from faith leaders to media. 
Following are examples of some of the 
accomplishments in the first 6 months:   
• Numerous HIV testing events hosted by 
churches, African American TV and radio 
personalities, and civic groups at their 
national conferences 
• Public service announcements by top 
entertainers to raise awareness about how 
African Americans can act against HIV 
• A call to action to all of the presidents of 
historically black colleges and universities 
to take a more active leadership role in 
addressing HIV/AIDS on their campuses and 
in the surrounding communities 
• Faith community events to provide HIV 
testing and HIV/AIDS support services for 
church members
• Increased coverage of HIV/AIDS among 
media outlets that reach African American 
communities 
• Engagement of major health insurance plans 
in local community mobilization events
 
To support the national response, an article 
titled, “Racial/Ethnic Disparities in Diagnoses 
of HIV/AIDS—33 States, 2001-2005,” 
was published in the MMWR ( http://www.
cdc .gov/mmwr/prev iew/mmwrhtml/
mm5609a1.htm ).
Information on the national response is also 
available on the NCHHSTP Web site ( http://
www.cdc.gov/hiv/topics/aa/resources/
reports/pdf/heightenedresponse.pdf ).
New HIV Testing Program Initiated 
In September 2007 NCHHSTP awarded $35 
million to 23 state and local health departments 
to increase HIV testing opportunities among 
populations disproportionately affected by HIV, 
primarily African Americans. It is estimated 
that the program will test more than 1 million 
persons and identify more than 20,000 new 
infections. The funds will support expanded HIV 
screening, testing, and linkage to care in clinical 
settings, such as emergency departments, 
community health centers, STD clinics, TB 
clinics, and correctional health facilities. 
While approximately 10 percent of the tests will 
be administered in non-clinical settings, the main 
focus of the program is to implement routine, 
voluntary HIV testing in healthcare settings, 
where opportunities to screen patients for HIV 
are often missed. Another special emphasis of 
the program is integrating HIV testing activities 
with screening and prevention activities for other 
infections, such as viral hepatitis, STDs, and TB. 
Because populations disproportionately affected 
by HIV are also disproportionately affected by 
these infections, integrating these services can 
significantly improve health. 
The program will help put into practice the 
“Revised Recommendations for HIV Testing 
of Adults, Adolescents, and Pregnant Women 
in Healthcare Settings,” and will support the 
Heightened National Response to the HIV/AIDS 
Crisis among African Americans initiative. The 
program is also consistent with CDC’s goal to 
reduce the number of new HIV infections in the 
United States and addresses the Healthy People 
2010 HIV prevention focus area.
 
Implementation of HIV Screening 
Recommendations 
In September 2006, CDC published new 
recommendations for health care providers 
designed to make voluntary HIV screening a 
routine part of medical care for all patients aged 
13 to 64. The recommendations aim to simplify 
the HIV testing process in health care settings 
and increase early HIV diagnosis among the 
estimated 250,000 HIV-positive Americans 
who are unaware of their infection. The 
recommendations, “Revised Recommendations 
for HIV Testing of Adults, Adolescents, and 
Pregnant Women in Healthcare Settings,” were 
published in MMWR ( http://www.cdc.gov/
mmwr/preview/mmwrhtml/rr5514a1.htm ).
Since publication of the recommendations, 
NCHHSTP has initiated a broad array of 
activities to facilitate their implementation, 
including a number of collaborations with 
various stakeholders. Some examples follow:  
 
• NCHHSTP initiated a collaborative effort 
with a wide range of professional medical 
associations at a meeting convened by 
the American Academy of HIV Medicine in 
October 2006. The Academy now coordinates 
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 six workgroups in conjunction with CDC to 
address various aspects of HIV screening, 
including reimbursement issues, linkage to 
care, and communications strategies.
• Regional workshops to promote HIV screening 
in emergency departments were held in FY 
2007 and continue during FY 2008. The 
workshops are based on a model that was 
highly effective in promoting perinatal HIV 
screening. At the workshops, multidisciplinary 
teams from local hospitals conduct strategic 
planning to initiate HIV screening. Follow-up 
to monitor progress is conducted 6-9 months 
following the workshop.
• NCHHSTP has also collaborated with other 
Federal agencies to implement the testing 
 recommendations. For example, NCHHSTP 
is collaborating with the Substance Abuse 
and Mental Health Services Administration 
(SAMHSA) on implementation plans for HIV 
 screening in substance abuse programs. 
NCHHSTP also participated in a consultation 
with HRSA to discuss implications of HIV 
screening for HRSA grantees.
 
Expanding Evidence-based Prevention 
Interventions 
Given the challenges of further reducing HIV 
infection rates, it is critical to focus on behavioral 
prevention efforts that are based on the best 
available scientific evidence. Evidence-based 
prevention interventions are a cornerstone of 
CDC’s HIV prevention program. NCHHSTP works 
to identify the most effective interventions, to 
package those interventions into toolkits for 
distribution to CBOs and health departments, 
and to offer training and assistance to ensure 
they are used effectively by a broad audience.
In January 2007 NCHHSTP published 
“Best Evidence Interventions: Findings from 
a Systematic Review of HIV Behavioral 
Interventions for U.S. Populations at High 
Risk, 2000-2004,” in the American Journal of 
Public Health (Lyles, et al., 2007). NCHHSTP 
conducted a systematic review of the scientific 
literature published from 2000 through 2004 
and identified 18 behavioral interventions 
with the best evidence of efficacy in reducing 
HIV risk (Lyles, et al., 2007). The article 
and other information about the 2000-2004 
efficacy review are available on CDC’s Web site 
( http://www.cdc.gov/hiv/topics/research/
prs/best-evidence-intervention.htm  ).
NCHHSTP has updated its review of the 
literature published from 1988 through 2005 
and identified an additional 31 evidence-based 
interventions, bringing the total to 49 evidence-
based HIV behavioral interventions. Some 
of these interventions will be packaged as 
toolkits and disseminated for use by prevention 
agencies across the United States through 
NCHHSTP’s Replicating Effective Programs (REP) 
projects and Diffusion of Effective Behavioral 
Interventions (DEBI) projects. To date, 7 of 
the 49 identified evidence-based interventions 
have been disseminated. An additional 16 are 
currently being packaged or are being prepared 
for dissemination in the near future. 
NCHHSTP is working to increase the number 
of interventions that are culturally appropriate 
and that target specific high-risk groups. Of the 
49 interventions, 28 were targeted or primarily 
tested among African Americans, and 10 were 
targeted or primarily tested among Hispanics.
  
Expedited Partner Therapy 
Expedited partner therapy (EPT) is the practice 
of providing treatment to partners of persons 
diagnosed with an STD without clinical 
examination or encounter with those partners. 
With EPT, the patient delivers either medication 
or a prescription to the partner. In 2006 the 
CDC recommended EPT as a useful option for 
treatment of partners of patients diagnosed 
with chlamydia or gonorrhea. 
NCHHSTP undertook policy initiatives to assist 
STD prevention programs with implementation 
of EPT. DSTDP assessed the legal barriers to 
HIV Screening Success:
New York City Health and Hospital 
Corp. 
The New York City Health and Hospital 
Corp., the largest health care provider 
in New York City, embarked on an HIV 
Testing Expansion Initiative in 2006. 
After training clinicians and staff, the 
facilities adopted the use of rapid HIV 
tests; offered HIV testing in outpatient 
clinics, inpatient care, and emergency 
rooms; integrated testing into routine 
care; and urged physicians to offer the 
test. The stated goals were to increase 
HIV tests from 50,000 a year to 
100,000 tests per year and to increase 
the number of patients who knew their 
HIV status. The initiative succeeded in 
increasing the number of HIV tests 
in FY 2006. More importantly, the 
number of persons diagnosed with 
HIV more than doubled, from 720 in 
FY 2005 to 1,514 in FY 2006.
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and facilitators of implementation of EPT at 
the state level. This legal research resulted in 
development of a Web-based tool for local public 
health practitioners interested in implementing 
EPT in their jurisdictions ( http://www.cdc.
gov/std/ept/legal/default.htm ). Additional 
policy initiatives include collaboration with the 
American Medical Association, which supported 
the practice of EPT through passage of a 
resolution at its June 2006 House of Delegates 
meeting; collaboration with the Council of State 
Governments to develop materials to educate 
state legislators about EPT; and collaboration 
with other Federal agencies to address policy 
issues, such as the use of the 340B Drug Pricing 
Program for EPT. CDC is pursuing collaborations 
with other national professional organizations 
for endorsement of EPT.
  
Monitoring the Impact of the HPV Vaccine 
NCHHSTP initiated activities to support the 
rollout of the new HPV vaccine during FY 2007. 
The vaccine protects against four HPV types, 
which together cause 70 percent of cervical 
cancers and 90 percent of genital warts.
The U.S. Food and Drug Administration (FDA) 
licensed the vaccine in 2007, and CDC’s 
Advisory Committee on Immunization Practices 
recommended its use for routine immunization 
of 11- to 12-year-old girls, and of girls as young 
as 9. The vaccine is also recommended for 13- 
to 26-year-old girls/women who have not yet 
received or completed the vaccine series. While 
the vaccine has been shown in clinical trials to be 
safe and efficacious, monitoring the real-world 
effectiveness of the HPV vaccine is critical, as 
the overall effectiveness in the U.S. population 
may depend on several factors. These include 
whether the girls/women being vaccinated are 
similar to the clinical trial populations, whether 
the women at highest risk for cervical cancer are 
being reached with vaccination, and whether 
other HPV types fill the niche left by vaccine 
HPV types in causing cancer.
NCHHSTP undertook a number of surveillance 
activities to assess the impact of the HPV 
vaccine, including: 1) Monitoring cervical 
precancerous lesions by establishing a network 
of geographically diverse sentinel sites from 
well-defined populations; 2) Monitoring changes 
in anogenital warts; and  3) Monitoring the 
behavioral impact of the HPV vaccine (e.g., 
Pap testing and sexual behavior). NCHHSTP 
continues to collaborate with the National Center 
for Immunization and Respiratory Diseases and 
NCCDPHP on HPV vaccine implementation.
  
Syphilis Elimination 
To continue the success of the Syphilis 
Elimination Effort (SE) initiated in 1999 to 
eliminate syphilis in the United States, NCHHSTP 
implemented several activities in FY 2007. 
NCHHSTP developed a new SE funding formula, 
which will be implemented in FY 2008. This 
was done to be more responsive to the evolving 
syphilis epidemic, wide variation in project area 
funding, and overall level funding. The formula 
was changed to ensure funds are directed to 
areas with the highest morbidity. NCHHSTP also 
standardized the collection of behavioral data 
associated with STDs, including syphilis, to 
provide a clearer picture of the STD epidemic. 
To improve monitoring of SE activities and 
progress toward meeting elimination objectives, 
NCHHSTP introduced guidance for Evidence-
Based Action Planning for Syphilis Elimination. 
Beginning in FY 2008, SE programs will be 
required to use an evidence-based action plan to 
guide the collection of information on the target 
populations, interventions provided, resources 
allocated, and outcomes to facilitate program 
assessment, improve effectiveness, and inform 
decisions about future program development.  
 
Infertility Prevention  
One of NCHHSTP’s key priorities for STD 
prevention is increasing chlamydia screening of 
young women in private health care facilities. 
Annual chlamydia screening of sexually-active 
women 25 years and younger is recommended 
by CDC and other professional organizations 
to detect and treat women before chlamydia 
progresses to pelvic inflammatory disease which 
can lead to infertility. The National Infertility 
Prevention Program, a collaboration between 
Reducing Health Disparities in 
Syphilis
• In 1997, prior to the National Plan 
to Eliminate Syphilis, the Black:
White syphilis rate ratio was 43:1.
• By 2005, rate ratio has dropped to 
5.4:1.
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 CDC and the Office of Population Affairs, funds 
chlamydia screening and treatment services for 
low-income, sexually active women attending 
family planning, sexually transmitted diseases, 
and other women’s healthcare clinics. However, 
a significant proportion of individuals screened 
or seeking medical care for STDs access 
services through the private sector. CDC set a 
priority to increase Chlamydia screening rates 
nationally and developed an initiative to engage 
partners in the private sector on this important 
reproductive health issue. 
As part of this initiative, CDC collaborated in FY 
2007 with the Partnership for Prevention on its 
study to estimate the health benefits to the U.S. 
population of increasing the use of preventive 
services from current rates to 90 percent. 
Chlamydia screening is one of the preventive 
services included. CDC also released a report of 
an external consultation that reviewed evidence 
on male chlamydia screening and made 
program recommendations ( http://www.
cdc.gov/std/chlamydia/ChlamydiaScreening-
males.pdf ). Finally, CDC collaborated with 
the Council of State Governments to produce 
materials to educate state-level policy makers 
about the importance of chlamydia screening.
 
Continued Declines in Viral Hepatitis 
Since 1995, the reported incidence of hepatitis 
A, B, and C has declined by 75 percent or 
more; current national incidence of hepatitis 
A (1.5 cases/100,000), hepatitis B (1.8 
cases/100.000) and hepatitis C (0.2 
cases/100,000) are all very low. These data 
both confirm and inform the efficacy of public 
health interventions, including vaccination (for 
hepatitis A and B), screening of the blood 
supply, and other health interventions, such as 
decreasing injection drug use. 
Declines in hepatitis B have placed the 
elimination of hepatitis B virus transmission in 
the United States within reach as a public health 
goal. With an eye toward that goal, NCHHSTP 
published an MMWR RR, December 8, 2006: 
"A Comprehensive Immunization Strategy to 
Eliminate Transmission of Hepatitis B Virus 
Infection in the United States: Recommendations 
of the Advisory Committee on Immunization 
Practices (ACIP) Part II: Immunization of 
Adults." This report outlines the strategy to 
eliminate hepatitis B virus transmission in the 
United States. 
This strategy for eliminating hepatitis B 
transmission includes a call for immunizing adults 
who are at high risk for hepatitis B. Toward that 
end, NCHHSTP developed a Hepatitis B Vaccine 
Initiative in FY 2007. Through this initiative, 
$20 million in funds was awarded to 51 state 
and local health departments for purchase 
of hepatitis B vaccine to immunize high-risk 
adults. The goal of the initiative is to hasten 
elimination of hepatitis B disease by vaccinating 
high-risk adults in recommended public health 
venues, including HIV clinics, STD clinics, and 
correctional facilities.
  
Healthy People in a 
Healthy World 
CDC spearheads efforts to improve global health 
through medical technology, international 
coalitions, government interventions, and basic 
behavior changes. NCHHSTP contributes to this 
global effort via international research in 
HIV/AIDS, viral hepatitis, STDs and TB, 
through its GAP and through technical assistance 
in areas such as TB control.  
Global AIDS Program 
GAP is a proud partner in PEPFAR, a 5-year, $15 
billion, multifaceted approach to combating 
HIV/AIDS in more than 120 countries 
around the world. 
As a PEPFAR implementing partner, GAP provides 
direct scientific and technical assistance to 
Ministries of Health, partner organizations, 
and other USG agencies. GAP develops cutting-
edge science and translates it into public health 
practice and service delivery by strengthening 
Ministries of Health capacity to build self-reliant 
national public health systems.
 
1.4 Million People on HIV/AIDS Treatment 
Globally 
As of September 2007, PEPFAR has supported 
life-saving antiretroviral treatment for 
approximately 1,445,000 men, women, and 
children through bilateral programs in sub-
Saharan Africa, Asia, and the Caribbean. Before 
President Bush announced PEPFAR in 2003, 
it was estimated that only 50,000 people in 
sub-Saharan Africa were receiving antiretroviral 
treatment. 
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In collaboration with other USG agencies, 
GAP has made significant contributions to 
unprecedented HIV treatment expansion, and 
provided critical support in human-capacity 
building, drug procurement and management, 
rehabilitation of laboratory and clinic facilities, 
linkage of HIV program with other health 
services, and building program sustainability. 
Following are a few highlights of other FY 
2007 accomplishments of GAP.
Building International Laboratory Capacity  
A good public health laboratory network is 
a cornerstone of a strong response to global 
HIV/AIDS. Without laboratory support, it is 
difficult to diagnose HIV infection and provide 
high-quality care and treatment for people 
living with HIV/AIDS. GAP is building capacity 
for high-quality laboratory services to assist 
with the rapid expansion of HIV treatment in 
resource-poor countries through PEPFAR, and 
the accompanying need for HIV diagnosis and 
associated care. 
In 2007 the GAP laboratory in Atlanta became 
the first CDC Atlanta laboratory to receive 
the internationally recognized College of 
American Pathologists (CAP) accreditation. 
This accreditation will facilitate critical external 
quality controls and quality assurance programs 
for CDC’s partner laboratories supporting PEPFAR 
throughout the world.
In addition, the CDC rapid HIV testing training 
package was distributed and customized 
for use in Botswana, Namibia, Kenya, 
Tanzania, Uganda, Zambia, and South Africa 
to accommodate country-specific policies 
and rapid testing algorithms. The customized 
training package is being used to train hundreds 
of counselors and nurses on proper procedures 
to perform and interpret HIV rapid testing for 
diagnosis.
In Africa, the need for laboratory diagnostic 
services has outpaced capacity; in 2007 
GAP intensified its capacity building efforts, 
providing the technical assistance to establish a 
Regional Integrated Laboratory Training Center 
in South Africa to build a well-trained workforce 
of laboratorians throughout Africa.
  
Innovation and Expansion of HIV Testing 
Counseling and testing provides an entry 
point to treatment and care, as well as a 
crucial opportunity for prevention education. 
Surveys in sub-Saharan African countries with 
high burden of HIV have shown that only 12 
percent of men and 10 percent of women in 
the general population have been tested for HIV 
and received their results. Many HIV-positive 
individuals in these countries encounter clinical 
settings due to illness. Findings from a growing 
number of studies indicate that uptake of HIV 
testing increases when testing is routinely 
discussed and offered in clinical settings. 
GAP is taking a lead role in provider-initiated 
testing and counseling (PITC) in medical facilities 
through PITC trainings and training curriculum 
development; pediatric testing and counseling 
in clinical settings training; and, in collaboration 
with the World Health Organization (WHO), 
development of normative guidance on PITC. 
These activities have helped Ministries of Health 
around the world to ensure that persons in high 
prevalence countries have an opportunity to get 
an HIV test during all medical encounters. 
TB is one of the most common opportunistic 
infections and the leading cause of death 
among people living with HIV/AIDS. The 
prevalence of HIV infection among patients in 
TB clinical settings is high—up to 80 percent 
in some countries. GAP, in collaboration with 
WHO, developed an implementation package 
for countries to scale up HIV testing in TB clinical 
settings, which includes a decision-making 
matrix, curriculum for training health providers, 
and job aides. This package was piloted and 
evaluated in three districts in Tanzania and has 
since been adapted and implemented in several 
other PEPFAR countries. 
  
Providing Tuberculosis Control Technical 
Assistance Internationally 
Because we live in a global economy and because 
most cases of TB in the United States are among 
foreign-born persons, it is critical for the United 
States to assist in TB control globally. NCHHSTP’s 
DTBE and GAP provide leadership and technical 
assistance in infection control, epidemiology, 
surveillance (including drug resistance surveys), 
program and laboratory services development, 
monitoring and evaluation, operations research 
and training, improving diagnostic services, 
and identifying clinical factors important to TB 
outcomes. These efforts build on the successful 
program to control TB in the United States. CDC 
collaborates with U.S. partners to reduce TB in 
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high-burden countries by developing guidelines, 
recommendations, and policies. Over the past 3 
years, CDC has supported TB control efforts in 
more than 25 countries on 5 continents. 
In addition to working closely with Ministries 
of Health in other countries, CDC works with 
multilateral organizations, such as WHO and the 
International Union Against TB and Lung Disease; 
foundations, including a Bill and Melinda Gates 
Foundation-funded collaboration and the 
Foundation for Innovative New Diagnostics; 
and nongovernmental organizations. CDC is a 
founding member of the Stop TB Partnership, 
a global effort of more than 500 governmental 
and nongovernmental organizations, housed by 
the WHO. Members of the Stop TB Partnership 
work toward achieving the 2006-2015 
Millennium Development Goals of reducing 
global TB deaths by 50 percent and the number 
of persons suffering from TB by 50 percent.
NCHHSTP staff provide ongoing technical 
assistance to foreign countries with a high 
burden of TB and to those having a strategic 
interest for TB control efforts in the United 
States. At least 75 such technical assistance 
visits were made in FY 2007. Staff also travel 
to international settings to provide training in 
epidemiology and research. For example, a 
team of CDC epidemiologists and technical 
experts recently collaborated with WHO and 
the Hague-based KNCV Tuberculosis Foundation 
to conduct a TB/HIV Planning & Operational 
Research Workshop in Kiev, Ukraine, in May 
2007. Participants included epidemiologists 
and physicians from Russia, Belarus, Moldova, 
and Ukraine. The workshop promoted TB/HIV 
collaborative activities at the national and 
regional levels, including an opportunity for each 
country team to develop a TB/HIV operational 
research proposal focused on improving 
operations between TB and HIV programs. The 
CDC team taught applied epidemiology and 
provided mentoring to country teams.
Eliminating Congenital Syphilis 
Congenital syphilis is a serious public health 
problem globally, accounting for an estimated 
1.5 million cases each year and resulting in 
up to 750,000 perinatal deaths, in addition to 
other significant perinatal morbidity. Congenital 
syphilis can be prevented by serological 
screening for syphilis during pregnancy with 
prompt treatment of those women found 
positive with intramuscular penicillin. However, 
fragmented antenatal health services, lack of 
appreciation of the burden and significant public 
health outcomes of congenital syphilis, as well 
as limited resources for screening have allowed 
this old disease to continue to cause substantial 
health problems in many developing countries. 
In response to this situation, WHO launched 
an initiative calling for the global elimination 
of congenital syphilis. NCHHSTP is supporting 
WHO in this effort by helping to characterize 
the global disease burden and health outcomes, 
and to identify indicators that countries 
can use to monitor programs’ progress and 
measure the impact of national and global 
activities directed toward SE. NCHHSTP is also 
supporting developing nations in building or 
sustaining laboratory infrastructure for reliable 
syphilis testing and developing and evaluating 
practical, inexpensive point-of-care tests to 
provide serological screening for syphilis as part 
of routine antenatal services in resource-poor 
settings in the developing world.
Global Viral Hepatitis Prevention
An NCHHSTP medical officer is assigned to 
WHO’s Expanded Programme on Immunisation 
(EPI) to act as the technical expert and focal 
point for viral hepatitis, with an emphasis on 
hepatitis B and hepatitis B-related activities. 
The medical officer plans, directs, and manages 
hepatitis B immunization activities, programs, 
and studies, and serves as expert consultant to 
WHO regional and country offices and Ministries 
of Health. Specific activities with which the 
medical officer has been involved include: 1) 
developing guidelines for introducing hepatitis 
B vaccine into routine childhood immunization 
programs; 2) coordinating technical support 
to WHO regions and countries for applications 
to the Global Fund for Childhood Vaccines 
(GFCV) for introduction of hepatitis B vaccine; 
3) coordinating evaluations of the hepatitis B 
vaccine introduction process; and 4) organizing 
a meeting to develop recommendations for 
monitoring the impact of routine childhood 
hepatitis B vaccination programs. NCHHSTP’s 
DVH also supports hepatitis prevention activities 
in China by supporting a WHO medical officer in 
WHO’s China office.  
Healthy People in Healthy 
Places 
CDC is working hard to ensure the places 
we live, work, and play have safe, healthy 
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environments. Controlling TB in communities is 
one of the ways CDC addresses this goal.  
 
TB Morbidity at All-time Low 
TB morbidity was at an all-time low in the 
United States in 2006, with 13,779 new cases 
reported by NCHHSTP in a 2007 report. This 
represents a 2.1 percent decrease from the 
previous year and the 14th consecutive year 
of a decline in reported TB cases. Since the 
1992 TB resurgence peak in the United States, 
the number of TB cases reported annually has 
decreased by 48 percent. The latest data show 
that deaths are also decreasing—from 657 
deaths in 2004 to 646 deaths in 2005—and 
that more than half of the states have low 
incidence of TB. In addition, the proportion 
of cases caused by organisms with primary 
multidrug resistance was less than 1 percent. 
While these are significant achievements, 
continued vigilance is warranted as the 
decreasing trend in the annual case rate has 
slowed from an annual average decline of 6.6 
percent for 1993-2002 to an annual average 
decline of 3.1 percent for 2003-2006. 
 
Assisting State and Local Health 
Departments  with TB Outbreaks and 
Laboratory Training 
In 2007 NCHHSTP provided assistance in 
six Epi-Aids (epidemiologic investigations) in 
Connecticut, Mississippi, Hawaii, Tennessee, 
and Michigan, and in multiple national and 
international sites for an airline traveler with 
MDR TB. On-site technical assistance was also 
provided in New York City and Las Vegas. Of 
these eight on-site investigations, five involved 
TB outbreaks, and three involved contact 
investigations. Four of the eight investigations 
involved drug-resistant TB. 
NCHHSTP also provided technical assistance to 
state TB control laboratories to help improve 
their capacity and effectiveness. The laboratory 
technical assistance consisted of: 1) conducting 
a training course for state public health 
laboratorians, 2) developing and disseminating 
performance indicators for TB laboratory 
services, and 3) developing tools and templates 
for TB laboratory service assessments.
  
Improving Health in Correctional Settings 
The Bureau of Justice Statistics reported in 2005 
that 2.2 million persons were incarcerated in 
the United States. Many persons in correctional 
settings have multiple risk factors for HIV, STD, 
viral hepatitis, and TB, and the prevalence for 
these diseases is higher than in the general 
population.
Using funds from the Bureau of Justice Statistics 
in partnership with the National Institute of 
Justice, NCHHSTP staff has taken the lead role 
in developing a passive surveillance system to 
track medical indicators associated with sexual 
violence in correctional facilities. Teams have 
visited several jails and prisons around the 
country to determine how medical and mental 
health complaints are processed. NCHHSTP staff 
members are now completing a surveillance 
form to be piloted in a number of facilities 
across the nation. Field testing is expected to 
start in early 2008.
Housing and Health 
Homelessness and housing instability are 
significant public health issues that increase 
the risks of HIV acquisition and transmission, 
and adversely affect the health of people living 
with HIV. NCHHSTP is exploring the impact 
of housing as a public health issue for people 
living with HIV in a collaborative effort with 
HUD. NCHHSTP is funding the Housing and 
Health Study, which is examining the impact 
of providing HUD-funded rental assistance 
for people living with HIV who are homeless 
or at risk for homelessness on their disease 
progression and their risks of transmitting HIV. 
Results from the study are expected in 2008. 
NCHHSTP is also working to address health 
issues related to homelessness through a newly 
formed workgroup made up of staff from across 
CDC.  
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 A Year In Review: 
Scientific Findings  
NCHHSTP conducts extensive biomedical and behavioral research to better understand the complex factors that lead 
epidemics. Research is an important part of 
CDC’s comprehensive approach to prevention. 
Excellence in science is a strategic imperative at 
CDC. This imperative mandates that we practice 
evidence-based science grounded in sound, 
peer-reviewed research and that we ensure a 
strong science base for public health action. 
NCHHSTP conducts or supports research in areas 
such as diagnostic tests, microbicides, vaccines, 
and behavioral research focused on eliminating 
health disparities. All extramural and intramural 
research activities conducted by or supported by 
NCHHSTP are subject to external peer review, 
ensuring rigor and quality, and that research 
funds support the most meritorious research 
ideas and projects. External review improves 
our science. An external peer review can provide 
expert review of quality, productivity, science, 
and direction. 
Five external peer review panels were convened 
in FY 2007 to review NCHHSTP programs, with 
a program from each division being reviewed. 
These panels reviewed the portfolios of the 
HIV/AIDS Epidemiology Branch, the GAP 
Laboratory Branch, the TB Epidemiologic Studies 
Consortium, the Viral Hepatitis Laboratory 
Branch, and the DSTDP. 
Further, research findings are published in peer-
reviewed journals. NCHHSTP staff published or 
have in press more than 400 publications in 
2007 (see http://www.cdc.gov/nchhstp/), 
including journal articles, book chapters, books, 
guidelines, and other publications.
NCHHSTP is also committed to mentoring 
young scientists interested in epidemiologic 
and prevention research. The extramural 
Minority HIV/AIDS Research Initiative (MARI), 
initiated in 2002, creates partnerships between 
CDC epidemiologists and researchers who are 
members of minority races and ethnicities and 
who work in communities of color. MARI funds 
epidemiologic and prevention studies of HIV in 
communities of color, and encourages the career 
development of young investigators. The Center 
also has a number of Epidemic Intelligence 
Service (EIS) officers, with 12 officers joining 
the Center in FY 2007. The EIS is the country’s 
critical epidemiology training service, combating 
the causes of major epidemics.
 
Healthy People in Every 
Stage of Life 
Detecting Drug-Resistant HIV 
CDC’s baseline HIV drug-resistant surveillance 
data from 11 states in 2007 revealed that 
about 10.4 percent of HIV-infected persons 
have HIV drug-resistant mutations. Primary 
HIV-1 drug resistance is a potentially significant 
clinical and public health concern because 
patients with drug resistance have an increased 
risk of treatment failure and may transmit drug-
resistant HIV to others.
These data were collected through CDC’s 
Variant, Atypical, and Resistant HIV Surveillance 
(VARHS) system, which examines remnant HIV 
diagnostic specimens to detect drug resistance. 
VARHS uses remnant HIV diagnostic sera or 
plasma to amplify and sequence relevant genes, 
and it collects electronic amino acid sequence 
data from private laboratories performing 
genotyping to estimate the prevalence of HIV 
drug resistance and HIV-1 subtypes among 
persons newly diagnosed and reported with 
HIV. Previous surveys have been based on 
convenience samples; VARHS is the first large 
surveillance system in the United States 
with 22 funded areas, thus enabling CDC to 
determine trends over time. Data from VARHS 
were presented at the14th Annual Conference 
on Retroviruses and Opportunistic Infections 
(CROI).
These data emphasize the importance of 
ongoing molecular HIV surveillance in the United 
States and will be useful for future evaluations 
of trends associated with the transmission 
of HIV drug-resistant mutations and subtype 
distribution. Ongoing data collection and 
analyses through routine surveillance also will 
inform HIV prevention and treatment program 
planning and vaccine development efforts, and 
alert CDC to the spread or clustering of atypical 
strains. 
In addition, CDC is developing and testing more 
sensitive tests for detecting mutations associated 
with HIV drug resistance. This is important 
because up to one-third of transmitted drug-
resistant HIV is not detected by conventional 
resistance testing, and this hidden resistance is 
strongly associated with poor virologic response 
to antiretroviral therapy (ART).
   
Project START Leads to HIV, STI Reduced 
Risk  
Data from Project START, a four-site intervention 
trial, demonstrated the efficacy of a sexual risk 
reduction intervention for young incarcerated 
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men that bridged incarceration and reentry back 
into the community. 
The study compared the effects of an enhanced 
multi-session intervention with a single-session 
intervention on the sexual risk behavior of 
young men released from prison. In the CDC 
study, young men, 18 to 29 years of age, 
were recruited from prisons in four states and 
systematically assigned to either a single-
session intervention conducted prior to release, 
or a multi-session enhanced intervention that 
was initiated in prison and continued after the 
participant was released. Both interventions 
addressed HIV, hepatitis, and other STIs; 
the enhanced intervention also addressed 
community reentry needs (e.g., housing, 
employment). Assessment data were collected 
before the intervention at 1, 12, and 24 weeks 
after the participant was released from prison. 
Data from the 522 men who participated in the 
trial showed that the enhanced intervention led 
to greater reductions in risk than did the standard 
intervention. Men in both groups reported 
similar rates of unprotected vaginal or anal sex 
during the 90 days prior to incarceration (85 
percent of men in the enhanced intervention 
and 89 percent of men in the single-session 
intervention). At 24 weeks, 68 percent of men 
assigned to the enhanced intervention reported 
unprotected sex, compared to 78 percent of 
those assigned to the single-session intervention 
(OR = 0.40; 95% CI, 0.18% to 0.88%).
The enhanced intervention was shown to 
significantly reduce unprotected sexual behaviors 
that are associated with the transmission of 
HIV and other STIs. In addition, this study has 
provided new data on the risk behaviors and 
experiences of incarcerated men during, before, 
and after incarceration that have implications 
for future prevention and research efforts. The 
enhanced intervention meets CDC’s Prevention 
Research Synthesis Project’s best evidence 
criteria of efficacy and is being packaged for 
national dissemination. Study results were 
published in the Am J Public Health 2006;96(1 
0):1854-1861.
 
The Collaborative Injection Drug Users 
Study III/Drug Users Intervention Trial  
(CIDUS III/DUIT)
The Collaborative Injection Drug Users Study 
III/Drug Users Intervention Trial (CIDUS III/
DUIT) is a collaborative, multi-site study funded 
by CDC to develop and evaluate a theory-based 
behavioral primary prevention intervention for 
young adult, HIV-seronegative and hepatitis C 
virus (HCV)-seronegative IDUs. This was the 
first study to test a behavioral intervention 
targeting young IDUs for primary HIV and HCV 
prevention. 
In the Peer Education Intervention, participants 
were trained to be peer educators and asked to 
talk with other young IDUs in their communities 
about HIV and HCV risk reduction as a means 
of affecting change in the participants’ own risk 
behaviors. We also developed a control condition 
of equal duration involving health-related videos 
and facilitated discussion (Video and Discussion 
Intervention) to control for the possible effect 
of increased attention paid to participants in 
the study. The study sites included Baltimore, 
Chicago, Los Angeles, New York, and Seattle.
The study found that a peer education 
intervention produced a 29 percent greater 
decline in overall injection risk 6 months 
post-intervention relative to a video and 
discussion intervention, and the peer education 
intervention produced a 76 percent decrease 
relative to baseline. Decreases were also 
observed for sexual risk behaviors, but they did 
not differ by trial arm. Overall, HCV infection 
incidence (18.4/100 person-years) did not 
differ across trial arms. No HIV seroconversions 
were observed.
This study provides information about the 
injecting and sexual practices of young, recently 
initiated IDUs, which will help to focus prevention 
efforts on the behaviors occurring at the time 
of greatest risk. It showed that interventions 
providing information, enhancing risk reduction 
skills, and motivating behavior change through 
peer education training can reduce injection 
risk behaviors, although risk elimination might 
be necessary to prevent HCV transmission. 
Recruitment and retention of young adult IDUs 
for complex intervention trials is complicated, 
yet feasible. The study findings were published 
in AIDS 2007;21:1923-1932.
 
Emergence of Quinolone Resistant Neisseria 
gonorrhoeae Prompts CDC to Change 
Recommendation  
The Gonococcal Isolate Surveillance Project 
(GISP) is a model national sentinel surveillance 
system that monitors antimicrobial resistance 
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 to Neisseria gonorrhoeae in the United States. 
On the basis of data from GISP, in 2007 CDC 
revised its treatment guidelines and no longer 
recommends the use of fluoroquinolones 
for the treatment of gonococcal infections 
and associated conditions such as pelvic 
inflammatory disease (PID).
 
Annually, GISP collects approximately 6,000 
urethral gonococcal isolates from males 
attending 26-30 STD clinics throughout the 
country and provides national data to guide 
treatment for gonococcal infections.
In 2005, 9.4 percent of the 6,199 isolates 
collected by GISP were resistant to ciprofloxacin, 
a fluoroquinolone. During January-June 2006, 
13.3 percent of 3,005 isolates collected 
were resistant. Among heterosexual males 
during the same time period, the prevalence 
of fluoroquinolone-resistant N. gonorrhoeae 
increased from 3.8 percent in 2005 to 6.7 
percent. 
The revision was published in “Update to 
CDC’s Sexually Transmitted Diseases Treatment 
Guidelines, 2006: Fluoroquinolones No Longer 
Recommended for Treatment of Gonococcal 
Infections” MMWR, 2007; 56:(14):332-
336. In addition to publishing the new 
recommendations in MMWR, the information 
was disseminated widely to program partners 
and health care practitioners through a Dear 
Colleague Letter, a national media telebriefing, 
and follow-up program recommendations to 
state and local health departments.
  
Assessing STD prevalence: 
Results from Two CDC Studies 
A study providing the first national estimate of 
prevalent HPV infection among females aged 
14-59 years in the United States was published 
in JAMA in February 2007. The study was 
conducted by NCHHSTP and the National Center 
for Health Statistics as a part of the National 
Health and Nutrition Examination survey 
(NHANES) during 2003-2004. Participants in 
the study were asked to submit a self-collected 
vaginal swab, and the specimen was tested for 
HPV. 
Overall, 26.8 percent of women 14-59 
years of age had an HPV infection detected, 
corresponding to 24.9 million females in this 
age range with prevalent HPV infection. Risk 
factors for HPV detected in our analysis included 
sexual behavior and demographic variables, 
including young age and marital status. These 
data can provide a baseline estimate of HPV 
prevalence to guide models evaluating impact 
and cost-effectiveness of an HPV vaccine. The 
article describing the study is “Prevalence of 
HPV Infection Among Females in the United 
States,” JAMA 2007; 297:813-819.
A second assessment surveyed chlamydia and 
gonorrhea among those 14-39 years of age in 
the United States. Sexual history information 
and urine specimens were collected in NHANES 
for the period 1999–2002. Prevalence of 
gonorrheal infection was 0.24 percent (95% 
CI, 0.16% to 0.38%). Prevalence of gonorrheal 
infection was higher among non-Hispanic 
black persons than among non-Hispanic 
white persons. Among those with gonorrheal 
infection, 46 percent also had chlamydial 
infection. Prevalence of chlamydial infection 
was 2.2 percent (CI, 1.8% to 2.8%) and was 
similar between males and females.
Among females, the highest prevalence was in 
those age 14-19 years of age; among males, it 
was highest among those 14-29 years of age. 
Prevalence was higher among non-Hispanic 
black persons than non-Hispanic white persons. 
The findings support current recommendations 
to screen sexually active females aged 25 years 
or younger for chlamydia, to retest infected 
females for chlamydial infection, and to co-treat 
individuals with gonorrhea for chlamydia. The 
article describing the study is “A Population-
Based Survey of Chlamydia and Gonorrhea 
among Persons 14-39 Years of Age in the 
United States, National Health and Nutrition 
Examination Survey (NHANES) 1999-2002,” 
Annals of Internal Medicine 2007;147:89-96.
  
Oysters Linked to Multistate Outbreak of 
Hepatitis A 
NCHHSTP collaborated with the FDA on an 
investigation of a multistate outbreak of 
hepatitis A in 2005, in what was the first large 
outbreak of hepatitis A associated with shellfish 
consumption in the United States in more 
than 15 years. The investigation confirmed 
that oysters harvested from Louisiana were 
the cause of the outbreak. Results of the 
investigation were published in the journal 
Clinical Infectious Diseases in February 2007. 
This was the first outbreak investigation in 
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which an identical hepatitis A virus sequence 
was obtained from both the implicated food 
product and the patients. The study received 
a Leveraging Collaboration Award from the 
FDA for the collaborative efforts of NCHHSTP 
and FDA.  
 
Healthy People in a 
Healthy World 
Lower Early Mortality Rates Among Patients 
Receiving Antiretroviral Treatment at Clinics 
Offering Cotrimoxazole Prophylaxis in 
Malawi 
In developed countries, studies have clearly 
demonstrated the effectiveness of cotrimoxazole 
prophylaxis (a readily available combination 
of two antibiotics) at reducing morbidity and 
mortality in HIV-infected individuals, including 
those on ART. In various settings in Africa, 
cotrimoxazole is associated with a 25 to 46 
percent reduction in mortality for HIV-infected 
individuals who are not on ART. Unique factors 
(e.g., prevalence and variety of opportunistic 
infections) in specific countries warrant 
continued evaluation of cotrimoxazole for HIV-
infected individuals on ART. 
The objective of this study was to determine 
whether patients attending ART clinics in 
Malawi that provide cotrimoxazole had lower 
early mortality rates, compared with patients 
attending clinics that do not provide the 
medication. Retrospective cohort data were 
collected from five treatment sites (clinics 
providing cotrimoxazole to all patients receiving 
ART) and six control sites (clinics similar 
to the treatment clinics, but not providing 
cotrimoxazole to patients receiving ART). The 
major finding was that ART patients at clinics 
offering cotrimoxazole had 40.7 percent lower 
mortality risk (p<0.001) during the first 6 
months of ART, compared with ART patients at 
similar clinics not offering cotrimoxazole. 
This finding builds on existing data demonstrating 
the benefit of cotrimoxazole. Cotrimoxazole is 
widely available in sub-Saharan Africa; when 
purchased in bulk, it costs only $6 per person 
per year, making it a very low-cost, low-tech, 
high-impact intervention. The article describing 
the study was published in J Acquir Immun Defic 
Syndr 46:56–61, July 19, 2007.
 
Successful Introduction of Routine  
Opt-Out HIV Testing in Antenatal Care in 
Botswana 
An essential component of prevention 
of mother-to-child transmission (PMTCT) 
services is antenatal HIV testing. In 2001 
CDC recommended making HIV testing a 
routine (opt-out) part of antenatal care, and 
most developed countries have adopted this 
testing strategy. However, in many developing 
countries, HIV tests for pregnant women are not 
routine and are treated differently from other 
medical tests, with counseling required before 
the decision to test is made. 
Botswana implemented national PMTCT services 
(including opt-in HIV testing) in 1999. Despite 
wide availability of PMTCT and antiretroviral 
services throughout the country, HIV testing 
uptake was low in the first years of the program. 
In December 2003, the President of Botswana 
announced that HIV testing would be routine 
in health care facilities in an effort to increase 
the number of people receiving appropriate 
HIV services. In 2004 CDC implemented a 
project to support the systematic introduction of 
routine HIV testing in antenatal clinics and to 
compare HIV testing rates, PMTCT intervention 
rates, and antenatal clinic attendance before and 
after the introduction of routine HIV testing.
The shift to routine HIV testing resulted in a 
dramatic increase in testing and in PMTCT 
service delivery without measurable adverse 
effects. In clinics studied in the first months of 
the new policy, the percentage of all HIV-infected 
women who learned their HIV status increased 
from 47 to 78 percent, and the percentage of 
women receiving PMTCT interventions increased 
from 29 to 56 percent. Routine HIV testing is 
now a standard practice in all antenatal clinics 
in Botswana, and >95 percent of all pregnant 
women in the country are tested for HIV. Efforts 
are underway to improve implementation of the 
routine testing policy for patients with TB and 
other medical conditions for which routine HIV 
testing is indicated. The article describing the 
study was published in J Acquir Immune Defic 
Syndr 45:102-107, May 1, 2007.
 
Diagnosis of HIV-1 Infection in Infants and 
Young Children Using Dried Blood Spots 
and Real-Time Reverse Transcription/
Polymerase Chain Reaction 
Because antiretroviral drugs are becoming more 
affordable, many resource-limited countries are 
expanding their programs to scale up PMTCT 
and treatment programs for infected infants. 
It is thus critical to identify HIV-infected infants 
early, so they an be linked to critical health 
services.
A simple diagnostic assay using dried blood 
spots (DBS) and real-time reverse transcription/
polymerase chain reaction (PCR) was developed 
to detect HIV infection in infants and children 
born to HIV-positive mothers so that the children 
can be referred to treatment and care in a timely 
manner. In this study, this assay was validated 
using DBS samples from Uganda and Cameroon. 
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 The mean age of the subjects from the studies 
was 34 weeks (range 8-80 weeks) in Uganda 
and 9.4 weeks (range 1 day to 46 weeks) 
in Cameroon. Simple, low-cost, and reliable 
assays such as this will be very useful for the 
implementation, monitoring, and evaluation of 
these PMTCT and infant treatment programs. 
The study was published in J Virologic Methods, 
2007 144:109-114, 2007.
 
Healthy People in Healthy 
Places  
Detecting TB Infection  
NCHHSTP examined the performance of 
two interferon-gamma release assays, the 
QuantiFERON TB and QuantiFERON TB Gold 
(QFT-G) tests, which are blood tests for the 
detection of TB infection. The key findings are 
that QFT-G appeared to offer similar sensitivity 
to the traditional tuberculin skin test (TST), and 
improved specificity (because antigens used in 
QFT-G do not cross react with Bacille Calmette-
Guerin (BCG), which is used as a vaccination 
against TB in many parts of the world or most non-
tuberculous mycobacteria, which are commonly 
found in the environment). As a consequence, 
use of QFT-G may offer substantially improved 
efficiency in the effort to complete treatment 
of latent tuberculosis infection (LTBI) in those 
most at risk to progress to TB disease. 
 
Understanding the Action of INH  
on a Highly INH-resistant TB strain  
In this study, the mechanism of isoniazid 
(INH) against a highly INH-resistant M. 
tuberculosis strain was explored, profiles 
of resistant and susceptible M. tuberculosis 
strains were compared, and how the resistant 
M. tuberculosis strain responds to INH at low 
and high concentrations was determined. The 
findings suggest that M. tuberculosis strains, 
which are resistant to low levels of INH, may be 
susceptible to high levels of INH, and that there 
may be benefit to treating INH-resistant bacteria 
with INH at a higher level that is effective and 
safe. Because INH is a first-line drug for the 
treatment of TB and INH resistance is fairly 
common, the findings of this study may have 
implications for TB treatment. 
Treating Latent Tuberculosis Infection 
A study at 19 U.S. and 2 Canadian sites concluded 
that treatment of LTBI can significantly decrease 
the TB burden in the United States. The study, 
conducted by CDC’s Tuberculosis Epidemiologic 
Studies Consortium, examined the scope and 
impact of treatment of LTBI in the United States 
and Canada. 
During 2002, an estimated 37,857 patients 
started LTBI treatment at 244 clinics surveyed. 
Based on these data, as well as on U.S. TB case 
rates and U.S. population data, CDC estimates 
that the total number of LTBI treatment starts 
in the United States was 291,000-433,000. 
Applying a 5 percent lifetime risk of TB without 
treatment and 20-60 percent treatment 
effectiveness using the total estimated 
LTBI patients, CDC further estimates that 
approximately 4,000-11,000 TB cases were 
prevented by treating LTBI.
  
Highlighted NCHHSTP 
Publications FY 2007 
Special journal issue: Moving Science Into 
Practice: The Role of Technology Exchange 
for HIV/STD Prevention. AIDS Education 
and Prevention 18 (Suppl. A), Fall 2006.
This special issue is a compilation of articles 
describing how evidence-based interventions are 
selected, adopted, adapted, and implemented 
in a wide array of community settings from 
health departments to CBOs. The purpose of 
this publication is to share lessons learned from 
health departments, CBOs and researchers on 
translating research to prevention practice, 
building national technology transfer systems, 
strategic planning for diffusing effective 
interventions to communities, and how 
interventions are being adapted for new target 
populations and communities.  
Special journal issue: Sexually Transmitted 
Disease Treatment Guidelines. Clin Infect 
Dis 2007; 44 (Suppl 3):S73-76. 
In April 2007, a special issue of Clinical 
Infectious Diseases (CID) was published, which 
provided background documents, tables of 
evidence, and rationale for recommendations 
included in the 2006 STD Treatment Guidelines. 
The Guidelines is one of CDC’s most widely used 
and referenced documents, and used throughout 
the United States and worldwide. It is the most 
widely referenced and authoritative source of 
information on STD treatment and prevention 
strategies for clinicians who provide care for 
persons with STDs or those at risk of STDs. 
However, if the Guidelines is to retain this level 
of acceptance and influence in the medical, 
academic, and public health communities, 
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NCHHSTP Award-Winning Authors
Winner of 2007 Charles C. Shepard 
Award in Assessment and Epidemiology 
Wolfgang Hladik, Sheila C. Dollard, 
Jonathan Mermin, Ashley L. Fowlkes, 
Robert Downing, Minaj M. Amin, Flora 
Banage, Esau Nzaro, Peter Kataaha, 
Timothy J. Dondero, Philip E. Pellett, 
and Eve M. Lackritz: Transmission 
of human herpesvirus 8 by blood 
transfusion. The New England Journal 
of Medicine 2006; 355:1331–
1338.
Synopsis: A study in Uganda provides 
strong evidence that HHV-8 is 
transmitted by blood transfusion and 
that risk may be diminished as the 
period of blood storage increases.
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the basis for the recommendations must be 
clear and convincing. This special issue of 
CID provides such needed evidence.  
Aral SO, Douglas JM Jr, eds. Lipshutz 
JA, assoc. ed. Behavioral Interventions 
for Prevention and Control of Sexually 
Transmitted Diseases. New York: Springer 
Science+SBM; 2007. 
This 24-chapter volume is the most 
comprehensive review of the current literature 
in behavioral interventions for STDs ever 
published. This book contains chapters dealing 
with a broad range of topics, including types of 
interventions and interventions appropriate for 
critical target populations for STD prevention, 
and it is intended to serve as an up-to-date, 
comprehensive resource for students and 
practitioners of public health as they learn 
about and implement behavioral interventions 
for STDs. 
Publication of Guidelines 
or Recommendations 
Quadrivalent Human Papillomavirus Vaccine: 
Recommendations of the Advisory Committee 
on Immunization Practices (ACIP). MMWR 
2007; 56(RR02); 1-24.  
CDC published recommendations for vaccine use 
in the United States in FY 2007. Genital HPV 
is the most common STI in the United States, 
with an estimated 6.2 million persons becoming 
newly infected every year. Persistent infection 
with oncogenic HPV types can cause cervical 
cancer in women. In 2006 it is estimated that 
over 9,000 new cases were diagnosed and 
approximately 4,000 women died from cervical 
cancer. HPV infection is also the cause of genital 
warts and is associated with other anogenital 
cancers. Two prophylactic HPV vaccines have 
been developed, and one was licensed for use 
in 2006. 
In 2004 an HPV workgroup, including staff from 
NCHHSTP, was formed at CDC to coordinate 
efforts and to work with ACIP to develop 
recommendations for HPV vaccine use. ACIP 
voted to recommend routine use of HPV vaccine 
in females 11–12 years of age and catch-up 
vaccination of females 13–26 in June 2006. 
The HPV vaccine ACIP Statement was published 
in MMWR in March 2007. Development of 
recommendations for use of the HPV vaccine 
provided guidance for vaccine providers around 
the country and allowed a Vaccine for Children 
resolution to be passed, opening the way for 
vaccine to be purchased on the CDC Federal 
contract at a reduced cost.
    
A Comprehensive Immunization Strategy 
to Eliminate Transmission of Hepatitis 
B Virus Infection in the United States: 
Recommendations of the Advisory 
Committee on Immunization Practices (ACIP) 
Part II: Immunization of Adults, MMWR RR, 
December 8, 2006.   
This report, the second of a two-part statement 
from ACIP, provides updated recommendations 
to increase hepatitis B vaccination of adults at 
risk for HBV infection. Hepatitis B vaccination 
is the most effective measure to prevent HBV 
infection and its consequences, including 
cirrhosis of the liver, liver cancer, liver failure, 
and death. In adults, ongoing HBV transmission 
occurs primarily among unvaccinated persons 
with behavioral risks for HBV transmission (e.g., 
heterosexuals with multiple sex partners, IDUs, 
and MSM) and among household contacts 
and sex partners of persons with chronic HBV 
infection. 
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NCHHSTP Award-Winning Authors
NCHHSTP Authors Win Award for Excellence in Behavior and Social Science Research 
in Public Health 
NCHHSTP authors of three journal articles won the Award for Excellence in Behavior and Social 
Science Research in Public Health in 2007.  The award is sponsored by the CDC Behavioral and 
Social Science Working Group. 
The winners were:
Bartholow BN, Goli V, Ackers M, McLellan E, Gurwith M, Durham M, Greenberg AE. Demographic 
and behavioral contextual risk groups among men who have sex with men participating in a 
Phase 3 HIV vaccine efficacy trial: Implications for HIV prevention and behavioral/biomedical 
intervention trials. Journal of Acquired Immune Deficiency Syndromes 2006;43:594–602. 
Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, Coutinho A, Liechty C, 
Madraa E, Rutherford G, Mermin J. Changes in sexual behavior and risk of HIV transmission 
after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006 Jan 2; 
20(1):85–92. 
Crepaz N, Lyles CM, Wolitski RJ, Passin WF, Rama SM, Herbst JH, Purcell DW, Malow RM, Stall 
R for the HIV/AIDS Prevention Research Synthesis (PRS) Team. Do prevention interventions 
reduce HIV risk behaviors among people living with HIV? A meta-analytic review of controlled 
trials. AIDS 2006 Jan 9;20(2):143-57.
A  Y E A R  I N  R E V I E W Sc i en t i f i c  F i nd i ng s
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Other budget lines at CDC support the Center’s 
health communications activities, health 
informatics activities, and leadership and 
management.  Also, Emerging Infectious Disease 
(EID) funds support surveillance for vaccine-
preventable STDs (Hepatitis B and HPV), and 
BUDGET
NCHHSTP receives funding from the Labor, HHS, and Education appropriation to support both its domestic and global 
programs.  Most funding comes through 
the HIV/AIDS, Viral Hepatitis, STD and TB 
prevention budget activity, and the Global 
Health budget activity.  In addition, NCHHSTP’s 
Global AIDS Program receives significant support 
from the Global HIV/AIDS Initiative (GHAI) 
account.  Other critical sources of support 
include the budget activities for CDC Leadership 
and Management, Emerging Infectious Disease, 
Food Safety (for hepatitis A), Health Marketing, 
and Health Informatics.
Funding for most domestic programs has 
remained level or declined slightly over the past 
4 years (see figure 1).  In 2007, additional 
funding of $45 million was directed to the 
President’s domestic HIV Testing Initiative. 
Of NCHHSTP’s $1 billion domestic budget, the 
majority of funds - nearly 70 percent - go to 
domestic HIV prevention programs, with the 
rest distributed to TB, STD and viral hepatitis 
prevention programs (see figure 2).  The 
majority of the overall domestic budget funds, 
about 87 percent, was distributed extramurally 
to state and local health departments, 
nongovernmental agencies, universities and 
other partners (see figure 3). 
Funding from the GHAI account for global 
activities of the Global AIDS Program has 
increased significantly to support the President’s 
Emergency Plan for AIDS Relief (see figure 4). 
FY 2008 transfers from the GHAI account are 
not yet available but are expected to be above 
2007 levels.
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Figure 1: NCHHSTP Domestic Program
Budget FY 2004-2008 
*HIV amounts  in  F Ys  2007 and 2008 ref lec t  Pres ident ’s  In i t ia t ive  for  HI V  tes t ing
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STD
16%
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13%
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Figure 2: Domestic HIV, Viral Hepatitis, STD,
and TB Prevention
Actual Funding, FY 2007
Total : $1.0 bil l ion
VH
TB
STD
HIV
surveillance for drug resistant infections (e.g. 
gonorrhea and XDR-TB).  In addition, some 
of NCHHSTP’s activities to prevent hepatitis A 
are supported through the Food Safety Budget 
activity. (See table 1.) 
A n n u a l  R e p o r t  F Y  2 0 0 7 
N
C
H
H
S
TP
 B
U
D
G
E
T
N C H H S T P  B U D G E T
Figure 3: Domestic HIV, Viral Hepatitis, STD,
and TB Prevention
Extramural and Intramural Obligations, FY 2007*
Total : $987.4 mill ion
*Excludes Gift Fund, Crada, Royalties and Reimbursable Funding.
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11%
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Figure 4: Global AIDS Program (GAP) Budget
HHS Appropriation
Foreign Operations
Appropriation
*2007 amounts for food safety and emerging infectious diseases reflect the addition of the Division of Viral Hepatitis to the Center in 2007.  EID funding also supports activities related to anti-microbial resistant STDs, MDR and 
XDR TB and monitoring related to vaccine-preventable diseases.
**In 2007, funding for health marketing was reduced to reflect the transfer of funds for the National Prevention Information Network (formerly known as the AIDS Clearinghouse) back to the HIV prevention budget line.
2005 2006 2007*
Leadership & Management $ 9,078,000 $ 6,925,000 $ 3,304,000
Business Support Services $ 1,261,000             - $ 482,000
EID             -             - $ 8,363,000
Food Safety (HAV)             -             -
            -
$ 693,000
Health Marketing $ 11,806,000 $ 11,290,000 $ 1,194,000**
Health Informatics  000,809,5 $ $ 5,320,000             -
HHS Minority AIDS Initiative $ 9,722,000 $ 8,390,000  $ 7,697,000
Congressional Projects $ 1,389,000             -
TABLE 1: OTHER CRITICAL SUPPORT RECEIVED FY 2005-2007
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NCHHSTP  PERFORMANCE INDICATORS
NCHHSTP’s domestic and international portfolios have been reviewed by the Office of Management and Budget (OMB) and found to be performing 
effectively.  Results are available at www.expectmore.gov  In collaboration with OMB, the Center has established 45 performance indicators to assess 
the extent to which our efforts result in real changes in health outcomes in the United States and abroad.  These indicators reveal that positive progress 
is being made; data on 55% of the indicators have improved just since 2002.  NCHHSTP is working to improve outcomes in those areas where progress 
has not been made and to establish data systems to assess performance in other areas.
FY 2007 NCHHSTP Performance Indicators (45 total)
All Divisions & Programs
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Trend toward goa l  (25) Trend away f rom goa l  (7) Data Not  Ava i lab le  (12) No Change (1)
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As we look toward FY 2008, there are a 
number of key domains in which NCHHSTP 
will prioritize resources and key activities.
Advance HHS, CDC, and NCHHSTP Priorities 
NCHHSTP will continue to be an active contributor 
to the development and implementation of 
CDC’s Health Protection Goals, and specifically 
will implement activities in support of key 
recommendations outlined in the recently 
published action plans. The CDC goals’ action 
plans highlight key cross-cutting priorities for 
improving health and provide a framework for 
investing to increase health impact. NCHHSTP 
will continue to align our investments and 
resources in support of relevant HHS priorities, 
and implement activities in support of the 
Center’s priorities—reducing health disparities, 
program collaboration and service integration, 
and maximizing global synergies.
Strengthen and Promote Prevention Science 
Robust science and a strong and evolving evidence 
base for our prevention activities remain the 
cornerstone of NCHHSTP programs. We remain 
committed to critically examining research gaps, 
and to funding and supporting the best science 
to assist us and our partners to make informed 
decisions on health spending. Having reviewed 
our extramural research activities in FY 2007, 
NCHHSTP is poised to identify strategic priorities 
for investment, better target research spending, 
and ensure that scarce resources are focused 
on the most important priorities. We commit to 
ensuring that our science is widely and quickly 
disseminated to a broad range of audiences, 
and that every opportunity for science to inform 
programmatic activities is used. In addition, 
NCHHSTP will continue to invest in training 
and mentoring junior scientists in cutting-edge 
scientific methodologies, up-to-date regulatory 
requirements, and dissemination of science, 
thereby ensuring that we continue to produce 
well-rounded scientists for the future.
Promote excellence, collaboration, and 
synergies in prevention programs
Excellence in programs is especially important 
as this is where the bulk of our investments 
lie, as well as where we can best leverage our 
investments for greater health impact. Excellence 
in programs means working more closely with 
our partners in the field to understand how our 
prevention investments are being deployed 
and where new or refocused investments are 
likely to have greatest gain. Most importantly, 
we will be committed to ensuring greater 
collaboration and cross-fertilization between our 
epidemiological and programmatic activities so 
that our research priorities and activities may 
be more readily translated into programmatic 
gains, and lessons learned from program 
implementation may more readily influence our 
research funding decisions. NCHHSTP will also 
commit to developing activities in the field of 
program science, or operational research, so 
that we can learn—in real time—the best 
ways to improve the quality of our program 
activities.
Strengthen and leverage partnerships 
As we look to FY 2008, the Center will continue 
to build on our strong collaborations and 
partnerships so that we take full advantage of 
these relationships to accelerate the elimination 
of HIV/AIDS, viral hepatitis, STDs, and TB. 
Robust partnerships will also be a key strategy 
as we move toward implementing more holistic, 
integrated, and comprehensive prevention 
models. NCHHSTP will continue to work with 
our traditional partners, as well as commit to 
expanding our reach, to involve nontraditional 
partners in the fight against HIV, viral hepatitis, 
STDs, and TB domestically and globally. A key 
component of our partnership strategy in FY 
2008 will be to identify novel ways to engage 
partners and the public in the work that we 
do. This will involve taking new risks in public 
and partner engagement, committing to listen 
to feedback from stakeholders, and being 
increasingly transparent in our actions and 
decision-making.
Strengthen and develop public health 
leaders 
NCHHSTP will continue to invest in the next 
generation of public health leaders who are 
needed to continue the fight against these 
devastating diseases. By funding student 
fellowships, welcoming new EIS Officers, 
recruiting the brightest and best talent, and 
developing our global and domestic workforce, 
NCHHSTP will continue to play an active role 
in ensuring that the new generation of public 
health workers understands and is committed 
to tackling our diseases. At the same time, we 
look forward to harnessing the enthusiasm and 
creativity of new leaders coming into our field 
and applying their expertise and insights to our 
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prevention activities. Leadership training and 
development will be particularly important for 
leaders throughout NCHHSTP, and opportunities 
for developing mentoring programs for staff 
and leaders will be actively sought and 
implemented.
Maximize Health Impact 
Finally, as we look toward the new fiscal year, 
NCHHSTP will continue to build on our past 
successes in increasing health impact. Whether 
measured by increases in treatment and care 
for people living with HIV globally, increasing 
the prevalence of HIV and STD testing, further 
reducing the incidence of TB and other infectious 
diseases, or increasing access to safe and 
effective vaccines for HPV and Hepatitis A and 
B, NCHHSTP will continue to fund and prioritize 
cost-effective, evidence-based prevention 
interventions. However, equally important will 
be a focus on the quality of our prevention 
services, and developing and using measures 
that more accurately describe the holistic and 
integrated nature and form of our prevention 
services and activities.
As we work with our partners and the public 
in 2008, NCHHSTP hopes to rise to the 
challenges posed by the changing demography 
and epidemiology of HIV/AIDS, viral hepatitis, 
STD, and TB in the United States and around 
the world, and the evolving polity and policy 
contexts. We look forward to working with you 
in the development of prevention science and 
programs and in the design and implementation 
of effective public health policies and practice.
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Performance Measures for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Domestic HIV/AIDS Prevention
•  Baseline established for 2002, unless otherwise indicated
•  Result established from 2006 data, unless otherwise indicated
•  Progress reflects performance data available as of 11/9/2007
GOAL 1:  DECREASE THE ANNUAL HIV INCIDENCE RATE
1. Decrease the annual HIV incidence. Not Available Not Available
BASELINEMEASURE RESULT
118 68 (2005)
10.33:1 8.71:1 (2005)
2. Decrease the number of pediatric AIDS cases.
3. Reduce the black:white rate ratio of HIV/AIDS diagnoses.*
4.1:1 3.5:1 (2005)4. Reduce the Hispanic:white rate ratio of HIV/AIDS diagnoses.*
29 335. Increase the number of states with mature, name-based HIV
    surveillance systems.
0 (2006) Not Available6. Increase the percentage of HIV prevention program grantees using
    Program Evaluation and Monitoring System (PEMS) to monitor
    program implementation.
7 147. Increase the number of evidence-based prevention interventions that
    are packaged and available for use in the field by prevention
    program grantees.
53 9878. Increase the number of agencies trained each year to implement
    Diffusion of Effective Behavior Interventions (DEBIs). 
Data Source:  Measure 1 - HIV/AIDS Incidence Surveillance in 34 states. Measures 2 - 5 - HIV/AIDS Reporting System (eHARS).
Measure 6 - Program Evaluation and Monitoring System (PEMS). Measure 7 - Replicating Effective Programs (REP) Project data.
Measure 8 - Diffusion of Effective Behavioral Interventions (DEBI) Tracking Database.
* Data for these measures is derived from 33 states with mature, stable HIV case surveillance.  These states are: Alabama, Alaska, Arizona, Arkansas, Colorado, 
Florida, Idaho, Iowa, Indiana, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New York, New Mexico, North 
Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming.  
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A P P E N D I X
•  Baseline established for 2002, unless otherwise indicated
•  Result established from 2006 data, unless otherwise indicated
•  Progress reflects performance data available as of 11/9/2007
GOAL 2:  DECREASE THE RATE OF HIV TRANSMISSION BY HIV-INFECTED PERSONS
1. Decrease the rate of HIV transmission by HIV-infected persons. Not Available Not Available
BASELINEMEASURE RESULT
Not Available Not Available2. Decrease risky sexual and drug using behaviors among persons at risk
    for transmitting HIV.
Data Source:  Measure 1 - Calculations of HIV incidence and prevalence, utilizing HIV/AIDS Incidence Surveillance System and special
prevalence studies; Measure 2  - Medical Monitoring Project (MMP).
GOAL 3:  DECREASE RISKY SEXUAL AND DRUG USING BEHAVIORS AMONG PERSONS AT RISK FOR ACQUIRING HIV
1. Decrease risky sexual and drug-using behaviors among persons at risk
    for acquiring HIV. 
MSM – 47% (2004) Not Available
BASELINEMEASURE RESULT
MSM – 18.9%  (2004) Not Available2. Increase the proportion of persons at risk for HIV who received HIV
    prevention interventions.
Data Source:  Measures 1 and 2 – National HIV Behavior Surveillance (NHBS) System.
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* Data for these measures is derived from 33 states with mature, stable HIV case surveillance.  These states are: Alabama, Alaska, Arizona, Arkansas, Colorado, 
Florida, Idaho, Iowa, Indiana, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New York, New Mexico, North 
Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming.
•  Baseline established for 2002, unless otherwise indicated
•  Result established from 2006 data, unless otherwise indicated
•  Progress reflects performance data available as of 11/9/2007
GOAL 4:  INCREASE THE PROPORTION OF HIV-INFECTED PEOPLE IN THE U.S. WHO KNOW THEY ARE INFECTED
MEASURE BASELINE RESULT
1. Increase the proportion of HIV-infected people in the United States
    who know they are infected.
2. Increase the proportion of persons with HIV-positive test results from
    publicly funded counseling and testing sites who receive their test results.
3. Increase the proportion of people with HIV diagnosed before progression
    to AIDS.*
74.5% (2003)
81%
78.1%
Not Available
83% (2005)
76.5% (2005)
Data Source:  Measure 1 – Special studies using eHARS.  Measure 2 - Counseling, Testing, and Referral System (CTR) � Program Evaluatio
and Monitoring System (PEMS). Measure 3 - eHARS.
n
GOAL 5:  INCREASE THE PROPORTION OF  HIV-INFECTED PERSONS WHO ARE
LINKED TO  PREVENTION AND CARE SERVICES
1. Increase the percentage of HIV-infected persons in publicly funded
    counseling and testing sites who were referred to Prevention
    Counseling and Referral Services (PCRS). 
Not Available Not Available
Not Available Not Available
Not Available Not Available
Not Available Not Available
BASELINEMEASURE RESULT
2. Increase the percentage of HIV-infected persons in publicly funded
    counseling and testing sites who were referred to medical care and
    attended their first appointment.
3. Increase the percentage of HIV-infected persons in publicly funded
    counseling and testing sites who were referred to HIV prevention services. 
4. Increase the percentage of HIV-infected persons in medical care who
    initiated medical care within three months of diagnosis. 
Data Source:  Measures 1 - 3 – Program Evaluation and Monitoring System (PEMS).  Measure 4 - Medical Monitoring Project (MMP).
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•  Baseline established for 2002, unless otherwise indicated
•  Result established from 2006 data, unless otherwise indicated
•  Progress reflects performance data available as of 11/9/2007
Viral Hepatitis Prevention
GOAL 6:  REDUCE THE RATES  OF  VIRAL HEPATITIS IN  THE UNITED STATES
1. Reduce the rate of new cases of hepatitis A (per 100,000 population). 11.3/100,000 (1997) 1.2/100,000
BASELINEMEASURE RESULT
2.6/100,000 (2003)
50% (2004)
1.6/100,000
Not Available
19 areas (2003) 36 areas
2. Reduce the rate of new cases of hepatitis B (per 100,000 population). 
3. Increase the proportion of individuals knowing their hepatitis C virus
    infection status. 
4. Increase the number of areas reporting chronic hepatitis C virus infections
    to CDC to 50 states and New York City and District of Columbia. 
Data Source:  Measures 1, 2, 4 – The National Notifiable Diseases Surveillance System (NNDSS); Measure 3 -- The National Health and 
Nutrition Examination Survey (NHANES).
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•  Baseline established for 2002, unless otherwise indicated
•  Result established from 2006 data, unless otherwise indicated
•  Progress reflects performance data available as of 11/9/2007
STD Prevention
* In FY 2002, the incidence of P&S syphilis in men was 3.8 per 100,000 (initial 2002 baseline).  However, because an outbreak of syphilis among men who 
have sex with men that occurred after 2002 has driven up the male syphilis rates, CDC is reporting a new baseline for 2006.
GOAL 7:  REDUCE THE RATES OF NON-HIV SEXUALLY TRANSMITTED DISEASES (STDS) IN THE UNITED STATES
1. Reduce pelvic inflammatory disease in the U.S. 197,000 106,000
BASELINEMEASURE RESULT
10.1% 13.1%
8.1:1 5.9:1
2. Reduce the prevalence of chlamydia among high-risk women under age 25.
5.6% 6.7%3. Reduce the prevalence of chlamydia among women under age 25, in
    publicly funded family planning clinics.
279/100,000 290/100,0004. Reduce the incidence of gonorrhea in women aged 15 to 44 (per100,000
    population).
2.4/100,000 3.3/100,0005. Eliminate syphilis in the U.S.
5.7/100,000
(2006)
5.7/100,0006.a) Reduce the incidence of P&S syphilis in men (per 100,000 population). *
1.1/100,000 1.0/100,0006.b) Reduce the incidence of P&S syphilis in women (per 100,000 population). 
10.2/100,000 8.5/100,0007. Reduce the incidence of congenital syphilis (per 100,000 live births). 
8. Reduce the racial disparity of P&S syphilis (reported ratio is black:white).
Data Source:  Measure 1 – The National Disease and Therapeutic Index (NDTI) (IMS Health).  Measure 2 -- The U.S. Department of Labor, 
National Job Training Program; CDC, IPP Chlamydia Prevalence Monitoring Project.  Measure 3 --  CDC, IPP Chlamydia Prevalence Monitoring 
Project. Measures 4 - 8 – STD Morbidity Surveillance System, CDC.
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•  Baseline established for 2002, unless otherwise indicated
•  Result established from 2006 data, unless otherwise indicated
•  Progress reflects performance data available as of 11/9/2007
TB Prevention
GOAL 8:  DECREASE THE RATE OF CASES OF TUBERCULOSIS AMONG U.S.-BORN PERSONS IN THE UNITED STATES
1. Decrease the rate of cases of TB among U.S.-born persons
    (per 100,000 population). 
2.9 2.3
BASELINEMEASURE RESULT
80.9%
93.0%
82.3% (2004)
92.2%
41.0% 43.3% (2004)
2. Increase the percentage of TB patients who complete a course of curative
    TB treatment within 12 months of initiation of treatment (some patients
    require more than 12 months).
3. Increase the percentage of TB patients with initial positive cultures who
    also have drug susceptibility results. 
4. Increase the percentage of infected contacts of infectious (Acid-Fast
    Bacillus (AFB) smear-positive) cases that are placed on treatment for
    latent TB infection and complete a treatment regimen. 
Data Source:  Measures 1 – 3 - The National TB Surveillance System.  Measure 4 -The National TB Surveillance System and the national 
Aggregate Reports for TB Program Evaluation. 
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1.  Number of people receiving HIV/AIDS treatment. 69,911 (2003) 1,358,375
BASELINEMEASURE RESULT
Focus Country Performance Measures (Includes all USG activities)*
854,800 (2004)
1,271,300 (2004)
3,901,543
4,011,797
1,791,900 (2004) 10,580,699
2.  Number of individuals provided with general HIV-related palliative care/
     basic health care and support during the reporting period, including TB.
3.  Number of pregnant women receiving PMTCT services, including
     counseling and testing during the reporting period.
4.  Number of individuals who received counseling and testing during the
     reporting period (counseling includes the provision of test results to clients).
Data Source:  Country Operational Plans (COPS) database.
GOAL 9:  THE GLOBAL AIDS PROGRAM WILL HELP IMPLEMENT THE PRESIDENT’S EMERGENCY PLAN FOR AIDS 
RELIEF IN 15 FOCUS COUNTRIES BY PARTNERING WITH OTHER USG AGENCIES TO ACHIEVE THE GOALS OF 
TREATING 2 MILLION HIV-INFECTED PEOPLE AND CARING FOR 10 MILLION PEOPLE INFECTED WITH OR 
AFFECTED BY HIV/AIDS BY 2008, AND PREVENTING 7 MILLION NEW HIV INFECTIONS BY 2010
* Performance is reported for entire USG efforts by the OGAC. Data are through September 2007.
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Overarching NCHHSTP Efficiency Measure
* This data was generated before the other bilateral countries received any specific guidance on monitoring and evaluation from OGAC.  Hece, indicator values 
for certain programmatic activities appear low or non-existent due to lack of available existing data.  Indicators include data from CDC, USAID, Peace Corps, 
and Department of Defense (DoD) and are based on each agency’s existing indicators for reporting which were mapped into PEPFAR indicators. The reported 
indicators are a subset of the full set of PEPFAR indicators, i.e., only those for which FY 2005 USG data is available.  Data are through September 2007, with 
exception of measure 3, which is through March 2007.
1.  Number of individuals receiving antiretroviral therapy at the end of the
     reporting period (includes PMTCT+ sites).
20,774 (2004) 276,965
BASELINEMEASURE RESULT
Other Bilateral Countries Performance Measures (Includes all USG activities)*
1,488 (2004)
145,133 (2004)
3,988
1,108,500
773,649 (2004) 5,249,131
2.  Number of individuals trained to provide laboratory-related activities.
3.  Number of pregnant women who received HIV counseling and testing
     for PMTCT and received their test results.
4.  Number of individuals who received confidential counseling and testing
during the reporting period.
Data Source:  GAP Planning and Reporting System and OGAC.
GOAL 10:  THE GLOBAL AIDS PROGRAM WILL HELP IMPLEMENT THE PRESIDENT’S EMERGENCY PLAN FOR AIDS 
RELIEF IN THE OTHER BILATERAL COUNTRIES  BY PARTNERING WITH OTHER USG AGENCIES , INTERNATIONAL 
AND HOST COUNTRY ORGANIZATIONS TO ACHIEVE THE GOALS OF PREVENTING NEW HIV INFECTIONS, TREATING 
HIV-INFECTED PEOPLE, AND CARING FOR PEOPLE INFECTED WITH OR AFFECTED BY HIV/AIDS
1. Increase the efficiency of core domestic HIV/AIDS surveillance as measured
    by the cost per estimated case of HIV/AIDS diagnosed each year.
$1,357 (2003) $887 (2005)
BASELINEEFFICIENCY MEASURE RESULT
Data Source:  Measure 1 - HIV/AIDS Reporting System (HARS) is used to collect state HIV and AIDS data; financial assistance information 
is drawn from administrative records and adjusted for inflation.   
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